TGFB1 and inflammatory bowel disease: In the present study, we evaluated, using in vitro cellular models, the ability of these different classes of drugs used in IBD to counteract two pivotal processes of intestinal fibrosis, including the differentiation of fibroblasts to activated myofibroblasts and the EMT induced by TGF-β1.